SIAS
NAVB

Shine Investment Advisory Services’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Shine Investment Advisory Services’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-980
Closed -$8K – 693
2017
Q3 		$8K Hold
980
– – ﹤0.01% 575
2017
Q2 		$10K Hold
980
– – 0.01% 522
2017
Q1 		$11K Buy
+980
New +$11.1K 0.01% 87

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Shine Investment Advisory Services's NAVB Position: Q4 2017 in Review

Shine Investment Advisory Services sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2017, closing a stake of 980 shares — an estimated $8K sold.

Shine Investment Advisory Services first reported a position in NAVB in Q1 2017 and held it in 3 quarters. The position peaked at $11K in Q1 2017. 54 funds tracked by Wall St. Rank hold NAVB as of Q4 2017.

  • Shine Investment Advisory Services reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2017 after selling out during the quarter.
  • Shine Investment Advisory Services sold 980 Navidea Biopharmaceuticals Inc. shares in Q4 2017, an estimated $8K.
  • Shine Investment Advisory Services first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2017 and held it in 3 quarters.
  • Shine Investment Advisory Services's Navidea Biopharmaceuticals Inc. position peaked at $11K in Q1 2017.
  • 54 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2017.

Based on Shine Investment Advisory Services's 13F filing for Q4 2017, filed 25 Jan 2018.